Published 6 October 2009, doi:10.1136/bmj.b3928
Cite this as: BMJ 2009;339:b3928

Research

Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City

¹ Instituto Nacional de Salud Pública, Cuernavaca, Mor, Mexico, ² Laboratorios de Biológicos y Reactivos de México (BIRMEX), Amores 1240, Col Del Valle, Delegación Benito Juárez. CP 03100, Distrito Federal, Mexico, ³ Instituto Nacional de Enfermedades Respiratorias (INER), Distrito Federal, México, ⁴ Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Distrito Federal, Mexico, ⁵ Subsecretariat of Health Prevention and Promotion, Distrito Federal, Mexico

Objective To evaluate the association of 2008-9 seasonal trivalent inactivated vaccine with cases of influenza A/H1N1 during the epidemic in Mexico.

Design Frequency matched case-control study.

Setting Specialty hospital in Mexico City, March to May 2009.

Participants 60 patients with laboratory confirmed influenza A/H1N1 and 180 controls with other diseases (not influenza-like illness or pneumonia) living in Mexico City or the State of Mexico and matched for age and socioeconomic status.

Main outcome measures Odds ratio and effectiveness of trivalent inactivated vaccine against influenza A/H1N1.

Results Cases were more likely than controls to be admitted to hospital, undergo invasive mechanical ventilation, and die. Controls were more likely than cases to have chronic conditions that conferred a higher risk of influenza related complications. In the multivariate model, influenza A/H1N1 was independently associated with trivalent inactivated vaccine (odds ratio 0.27, 95% confidence interval 0.11 to 0.66) and underlying conditions (0.15, 0.08 to 0.30). Vaccine effectiveness was 73% (95% confidence interval 34% to 89%). None of the eight vaccinated cases died.

Conclusions Preliminary evidence suggests some protection from the 2008-9 trivalent inactivated vaccine against pandemic influenza A/H1N1 2009, particularly severe forms of the disease, diagnosed in a specialty hospital during the influenza epidemic in Mexico City.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

The science and art of medicine

Fiona Godlee
BMJ 2009 339: b4125. [Extract] [Full Text]

The future of influenza vaccines

Menno D de Jong and Rogier W Sanders
BMJ 2009 339: b4014. [Extract] [Full Text]

This article has been cited by other articles:

• Wenzel, R. P., Edmond, M. B. (2009). Preparing for 2009 H1N1 Influenza. NEJM 361: 1991-1993 [Full text]  
• Jong, M. D d., Sanders, R. W (2009). The future of influenza vaccines. BMJ 339: b4014-b4014 [Full text]  

Rapid Responses:

Read all Rapid Responses

Conspicuous selection bias is the likeliest explanation for findings of seasonal vaccine protection against pandemic H1N1 in Mexico City

Danuta M. Skowronski, et al.
bmj.com, 12 Oct 2009 [Full text]

Re: Conspicuous selection bias is the likeliest explanation for findings of seasonal vaccine protection against pandemic H1N1 in Mexico City

seshubabu Gosala
bmj.com, 22 Oct 2009 [Full text]

Authors’ response to Skowronski and colleagues

Jose Luis Valdespino-Gómez, et al.
bmj.com, 10 Nov 2009 [Full text]

Online poll

Find out more on doc2doc >>